CBI Stock Overview
Clal Biotechnology Industries Ltd. is a private equity and venture capital firm specializing in development stage, pre-clinical; incubation, seed, start-up, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Clal Biotechnology Industries Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪0.47 |
| 52 Week High | ₪0.65 |
| 52 Week Low | ₪0.37 |
| Beta | 0.80 |
| 1 Month Change | 11.76% |
| 3 Month Change | 27.01% |
| 1 Year Change | -25.43% |
| 3 Year Change | -81.30% |
| 5 Year Change | -82.43% |
| Change since IPO | -94.87% |
Recent News & Updates
Recent updates
The Market Doesn't Like What It Sees From Clal Biotechnology Industries Ltd.'s (TLV:CBI) Revenues Yet
Apr 18
Calculating The Fair Value Of Clal Biotechnology Industries Ltd. (TLV:CBI)
Jul 14Does Clal Biotechnology Industries (TLV:CBI) Have A Healthy Balance Sheet?
Jan 19Investors Shouldn't Be Too Comfortable With Clal Biotechnology Industries' (TLV:CBI) Robust Earnings
Mar 25Clal Biotechnology Industries (TLV:CBI) Seems To Use Debt Quite Sensibly
Mar 24Introducing Clal Biotechnology Industries (TLV:CBI), The Stock That Zoomed 121% In The Last Year
Feb 16
What Kind Of Shareholders Own Clal Biotechnology Industries Ltd. (TLV:CBI)?
Jan 12Is Clal Biotechnology Industries (TLV:CBI) Using Too Much Debt?
Dec 07Shareholder Returns
| CBI | IL Biotechs | IL Market | |
|---|---|---|---|
| 7D | 2.4% | 3.3% | -0.2% |
| 1Y | -25.4% | 5.1% | 7.1% |
Return vs Industry: CBI underperformed the IL Biotechs industry which returned 5.1% over the past year.
Return vs Market: CBI underperformed the IL Market which returned 7.1% over the past year.
Price Volatility
| CBI volatility | |
|---|---|
| CBI Average Weekly Movement | 5.5% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in IL Market | 8.0% |
| 10% least volatile stocks in IL Market | 3.1% |
Stable Share Price: CBI has not had significant price volatility in the past 3 months.
Volatility Over Time: CBI's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | n/a | Assaf Segal | www.cbi.co.il |
Clal Biotechnology Industries Ltd. is a private equity and venture capital firm specializing in development stage, pre-clinical; incubation, seed, start-up, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing. It prefers to invest in life sciences, medical devices, biopharmaceutical technologies, and biotechnology companies. The firm seeks to invest in companies based in United States, and Israel.
Clal Biotechnology Industries Ltd. Fundamentals Summary
| CBI fundamental statistics | |
|---|---|
| Market cap | ₪74.50m |
| Earnings (TTM) | -₪31.05m |
| Revenue (TTM) | ₪104.00k |
716.4x
P/S Ratio-2.4x
P/E RatioIs CBI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CBI income statement (TTM) | |
|---|---|
| Revenue | ₪104.00k |
| Cost of Revenue | ₪0 |
| Gross Profit | ₪104.00k |
| Other Expenses | ₪31.16m |
| Earnings | -₪31.05m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.20 |
| Gross Margin | 100.00% |
| Net Profit Margin | -29,856.73% |
| Debt/Equity Ratio | 25.5% |
How did CBI perform over the long term?
See historical performance and comparison